Abstract
Hepatitis C, a leading cause of chronic liver disease globally, is caused by Hepatitis C Virus (HCV), a hepatotropic RNA virus. HCV infection starts with an acute infection, mostly subclinical, which ultimately leads to chronic hepatitis in about 80% of the infected cases. HCV is classified into 6 major genotypes and numerous subtypes. The global prevalence of HCV infection is about 1.6% with a majority of these infections being in adults. There is widespread heterogeneity in the prevalence of different genotypes of HCV in different geographical regions of the world. While genotype 1 is the most common worldwide, different regions of the world report variations in the prevalence of the other genotypes. Genotype 3 is the commonest genotype in India, but there is a wide variation in the distribution of the other genotypes in different parts of the country; genotype 6, a comparatively rarer genotype, has been reported frequently from the northeast part of India. With the introduction of new oral drugs, the Directly Acting Antivirals (DAA), the management protocols of hepatitis C has undergone dramatic transformation, with a paradigm shift towards an all-oral interferon-free regimen. However, developing countries like India still face a challenge with respect to accessibility and affordability of such newer regimens. Furthermore, the differences in genotypic distributions in India, with a higher prevalence of genotype 3, which is more difficult to treat, makes the situation even more challenging. As newer antivirals are being universally used to manage HCV infection, economically weaker countries like India should incorporate these changes in treatment guidelines soon. However, till substantial evidence on the efficacy of the newer regimens is accrued in the Indian population, and issues on cost and accessibility are addressed, it may not yet be prudent enough to altogether discard the existing conventional modes of HCV therapy.
Highlights
Hepatitis C is a blood-borne viral infection that is caused by Hepatitis C Virus (HCV), a hepatotropic Ribonucleic Acid (RNA) virus, with a propensity to affect the liver
According to the current guidelines antiviral treatment is recommended for all patients with chronic HCV infection, except those with limited life expectancy due to non-hepatic causes [12]
Three regimens are recommended for genotype 3 treatmentnaive patients [12,18]: (1) daclatasvir plus sofosbuvir for 12 weeks, (2) daclatasvir plus sofosbuvir, with or without ribavirin, for 24 weeks, or (3) sofosbuvir plus ribavirin plus peginterferon for 12 weeks
Summary
Hepatitis C is a blood-borne viral infection that is caused by Hepatitis C Virus (HCV), a hepatotropic RNA virus, with a propensity to affect the liver. It is recognised as a major public health problem worldwide responsible for chronic liver disease and a variety of extrahepatic manifestations. HCV is an enveloped positive stranded Ribonucleic Acid (RNA) virus belonging to genus Hepacivirus in the family Flaviviridae It was first detected in 1989 using molecular biology techniques after extensive testing of serum from experimentally infected animals [3]. This has led it to be an enigmatic challenge for both clinicians and researchers
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
